Online inquiry

IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3847MR)

This product GTTS-WQ3847MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IFNAR1&IFNAR2 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P48551
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3847MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ34MR IVTScrip™ mRNA-Anti-S, 2130(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 2130
GTTS-WQ1893MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ582MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ9069MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMC-A12
GTTS-WQ8956MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ3916MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ1029MR IVTScrip™ mRNA-Anti-MET, ABBV-399(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-399
GTTS-WQ6451MR IVTScrip™ mRNA-Anti-HA, CT-P23(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CT-P23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW